Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study

• Eman Zeyad I. Elmekaty ,

  Roles Conceptualization, Methodology, Writing – original draft

  * E-mail: Eelmekaty@hamad.qa

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  https://orcid.org/0000-0002-4761-1939

  ⨯
• Rim Alibrahim,

  Roles Data curation, Writing – original draft

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Rania Hassanin,

  Roles Data curation, Writing – original draft

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Sitelbanat Eltaib,

  Roles Data curation

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Ahmed Elsayed,

  Roles Data curation, Validation

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Fatima Rustom,

  Roles Validation

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Mohamed Izham Mohamed Ibrahim,

  Roles Formal analysis, Visualization, Writing – original draft

  Affiliation Clinical Pharmacy & Practice Department, College of Pharmacy, QU Health, Qatar University, Doha, Qatar

  ⨯
• Mohammed Abu Khattab,

  Roles Resources, Validation, Writing – original draft

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Hussam Al Soub,

  Roles Resources, Validation, Writing – review & editing

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Muna Al Maslamani,

  Roles Resources

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯
• Abdullatif Al-Khal

  Roles Resources

  Affiliation Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

  ⨯